Tarsus Pharmaceuticals, Inc.
TARS
Ранг среди акций
#4646
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Цена акции
$69.68
Рыночная капитализация
$3.26B
Изменение (1 день)
2.36%
Изменение (1 год)
-4.46%
Страна
US
Торговля Tarsus Pharmaceuticals, Inc. (TARS)
Категория
Healthcare
EPS для Tarsus Pharmaceuticals, Inc. (TARS)
EPS по состоянию на June 2026 TTM: $-1.09
Согласно последним финансовым отчетам и цене акций Tarsus Pharmaceuticals, Inc., текущий EPS компании (TTM) составляет $-1.09. В конце 2023 EPS компании составлял $-4.62, больше, чем показателю 2022 года, равному $-2.52.
История EPS компании Tarsus Pharmaceuticals, Inc. с 2018 по 2026
EPS на конец каждого года
| Год | EPS | Изменить |
|---|---|---|
| 2026 (TTM) | $-1.09 | -64.50% |
| 2024 | $-3.07 | -33.55% |
| 2023 | $-4.62 | 83.33% |
| 2022 | $-2.52 | 276.12% |
| 2021 | $-0.67 | -49.24% |
| 2020 | $-1.32 | 450.00% |
| 2019 | $-0.24 | -22.58% |
| 2018 | $-0.31 | 0.00% |
EPS для аналогичных компаний или конкурентов
| Компания | EPS | Разница в EPS | Страна |
|---|---|---|---|
| $17.32 | -1,688.99% |
US
|
|
| $-7.98 | 632.11% |
US
|
|
| $-5.29 | 385.32% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,644.95% |
NL
|
